High perivascular fat attenuation index (≥−70.1 HU) on coronary CTA significantly predicted increased cardiac mortality in derivation (HR 9.04) and validation (HR 5.62) cohorts.
Does perivascular fat attenuation index (FAI) predict all-cause and cardiac mortality in patients undergoing coronary CTA?
3,912 consecutive patients undergoing clinically indicated coronary CTA (1,872 in derivation cohort, median age 62, 63% male; 2,040 in validation cohort, median age 53, 55% male) in Germany and USA.
Perivascular fat attenuation index (FAI) mapping around the proximal right coronary artery on coronary CTA
All-cause mortality and cardiac mortalityhard clinical
Perivascular FAI measured on routine coronary CTA provides a quantitative measure of coronary inflammation that significantly improves cardiac risk prediction and restratification beyond current state-of-the-art assessment.
Absolute Event Rate: 0% vs 0%
SummaryBackgroundCoronary artery inflammation inhibits adipogenesis in adjacent perivascular fat. A novel imaging biomarker—the perivascular fat attenuation index (FAI)—captures coronary inflammation by mapping spatial changes of perivascular fat attenuation on coronary computed tomography angiography (CTA). However, the ability of the perivascular FAI to predict clinical outcomes is unknown.MethodsIn the Cardiovascular RISk Prediction using Computed Tomography (CRISP-CT) study, we did a post-hoc analysis of outcome data gathered prospectively from two independent cohorts of consecutive patients undergoing coronary CTA in Erlangen, Germany (derivation cohort) and Cleveland, OH, USA (validation cohort). Perivascular fat attenuation mapping was done around the three major coronary arteries—the proximal right coronary artery, the left anterior descending artery, and the left circumflex artery. We assessed the prognostic value of perivascular fat attenuation mapping for all-cause and cardiac mortality in Cox regression models, adjusted for age, sex, cardiovascular risk factors, tube voltage, modified Duke coronary artery disease index, and number of coronary CTA-derived high-risk plaque features.FindingsBetween 2005 and 2009, 1872 participants in the derivation cohort underwent coronary CTA (median age 62 years range 17–89). Between 2008 and 2016, 2040 patients in the validation cohort had coronary CTA (median age 53 years range 19–87). Median follow-up was 72 months (range 51–109) in the derivation cohort and 54 months (range 4–105) in the validation cohort. In both cohorts, high perivascular FAI values around the proximal right coronary artery and left anterior descending artery (but not around the left circumflex artery) were predictive of all-cause and cardiac mortality and correlated strongly with each other. Therefore, the perivascular FAI measured around the right coronary artery was used as a representative biomarker of global coronary inflammation (for prediction of cardiac mortality, hazard ratio HR 2·15, 95% CI 1·33–3·48; p=0·0017 in the derivation cohort, and 2·06, 1·50–2·83; pInterpretationThe perivascular FAI enhances cardiac risk prediction and restratification over and above current state-of-the-art assessment in coronary CTA by providing a quantitative measure of coronary inflammation. High perivascular FAI values (cutoff ≥–70·1 HU) are an indicator of increased cardiac mortality and, therefore, could guide early targeted primary prevention and intensive secondary prevention in patients.FundingBritish Heart Foundation, and the National Institute of Health Research Oxford Biomedical Research Centre.
Building similarity graph...
Analyzing shared references across papers
Loading...
Evangelos K. Oikonomou
Cardiac Imaging
Mohamed Marwan
Cardiac Imaging
Milind Y. Desai
Cardiac Imaging
The Lancet
University of Oxford
University College London
Cleveland Clinic
Building similarity graph...
Analyzing shared references across papers
Loading...
Oikonomou et al. (Tue,) reported a other. High perivascular fat attenuation index (≥−70.1 HU) on coronary CTA significantly predicted increased cardiac mortality in derivation (HR 9.04) and validation (HR 5.62) cohorts.
synapsesocial.com/papers/698cd14d0f5172d9365dbe91 — DOI: https://doi.org/10.1016/s0140-6736(18)31114-0
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: